Retatrutide Phase 3 Results: TRIUMPH Trial Series Explained

Pharmaceutical development follows a rigorous path from laboratory discovery to patient access, and the Phase 3 clinical trial is the most critical step. Phase 2 told us retatrutide works -- 24% average weight loss in 338 patients is a powerful signal. But Phase 3 must confirm those results in thousands of patients across diverse populations, identify rare safety events, and generate the data package the FDA requires for approval. For retatrutide, that Phase 3 program is called TRIUMPH, and it represents one of the most ambitious obesity drug development efforts ever undertaken.

Why Phase 3 Matters

Phase 2 trials are designed to establish whether a drug works and to identify the best doses for further development. Phase 3 trials answer more demanding questions:

• Confirmation of efficacy: Does the drug work in larger, more diverse populations? Phase 2 enrolled 338 participants; Phase 3 collectively enrolls thousands.
• Safety in real-world populations: Larger trials capture rare adverse events that small Phase 2 studies cannot detect. An event occurring in 1 in 1,000 patients will not show up in a 338-person trial.
• Specific population validation: Do results hold in patients with diabetes? In patients with cardiovascular disease? In different ethnic and demographic groups?
• Long-term outcomes: Phase 3 trials typically run longer than Phase 2, providing data on sustained efficacy, long-term safety, and what happens after 48+ weeks of treatment.
• Regulatory requirements: The FDA requires Phase 3 data for new drug approval. No amount of impressive Phase 2 data can substitute for successfully completed Phase 3 trials.

The TRIUMPH Program: Trial by Trial

TRIUMPH-1: The Pivotal Obesity Trial

TRIUMPH-1 is the flagship trial that will determine whether retatrutide is approved for weight management in adults with obesity. This is the most important trial for the broadest potential patient population.

• Population: Adults with BMI 30 or higher, or BMI 27+ with at least one weight-related comorbidity, without type 2 diabetes.
• Design: Randomized, double-blind, placebo-controlled. Participants receive retatrutide at selected doses or placebo via weekly subcutaneous injection.
• Duration: Approximately 72 weeks of treatment -- significantly longer than the 48-week Phase 2 trial. This extension is critical because Phase 2 weight loss curves had not plateaued at 48 weeks, suggesting continued weight loss beyond what Phase 2 measured.
• Primary endpoints: Percentage change in body weight from baseline and proportion of participants achieving 5% or greater weight loss at 72 weeks.
• Key secondary endpoints: Proportion achieving 10%, 15%, 20%, and 25%+ weight loss; changes in waist circumference, blood pressure, lipids, and other cardiometabolic markers.
• Expected enrollment: Over 1,500 participants across multiple countries.

If Phase 2 results hold, TRIUMPH-1 could show average weight loss exceeding 24% at 72 weeks -- potentially approaching 28-30% given the non-plateauing trajectory seen at 48 weeks. This would represent the highest weight loss ever achieved with a pharmaceutical agent and would approach typical bariatric surgery results.

TRIUMPH-2: Obesity with Type 2 Diabetes

Patients with type 2 diabetes typically lose less weight on GLP-1 medications than patients without diabetes. TRIUMPH-2 tests whether retatrutide's triple mechanism can overcome this attenuation.

• Population: Adults with type 2 diabetes and BMI 27+.
• Unique considerations: The glucagon receptor component adds complexity in diabetes management. Glucagon raises blood sugar, so the balance between glucagon's glycemic effects and the counteracting GLP-1/GIP effects is particularly important in this population.
• Key endpoints: Weight loss and A1C reduction. Phase 2 data in patients with diabetes showed A1C reductions of up to 2.02%, which would make retatrutide among the most potent glucose-lowering agents ever studied.
• Clinical significance: If retatrutide can produce both substantial weight loss and superior glucose control in patients with type 2 diabetes, it could become a first-line therapy for this large patient population.

TRIUMPH-3: Cardiovascular Outcomes

Cardiovascular outcomes trials (CVOTs) are the gold standard for demonstrating that a medication reduces heart attacks, strokes, and cardiovascular death. The SELECT trial established this benefit for semaglutide; TRIUMPH-3 aims to do the same for retatrutide.

• Population: Adults with obesity and established cardiovascular disease or high cardiovascular risk.
• Primary endpoint: Major adverse cardiovascular events (MACE) -- typically defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke.
• Duration: CVOTs are event-driven trials, meaning they continue until enough cardiovascular events have occurred to draw statistical conclusions. This typically requires 3-5 years of follow-up.
• Why it matters: A positive CVOT would position retatrutide as both a weight loss and cardiovascular protective agent, dramatically expanding its potential use and insurance coverage. The SELECT trial's success with semaglutide set the precedent.
• Timeline: Given the long follow-up required, TRIUMPH-3 results are not expected until 2028-2029 at the earliest. However, FDA approval for the obesity indication does not require CVOT completion -- it can be filed based on TRIUMPH-1 data.

TRIUMPH-4: Fatty Liver Disease (MASH)

Perhaps the most scientifically exciting trial in the program, TRIUMPH-4 studies retatrutide in patients with biopsy-confirmed MASH. As detailed in our retatrutide and fatty liver article, the drug's glucagon component gives it a unique mechanistic advantage for liver fat reduction.

• Population: Adults with biopsy-confirmed MASH (metabolic dysfunction-associated steatohepatitis) with fibrosis stage F1-F3.
• Primary endpoints: MASH resolution without worsening fibrosis, and/or fibrosis improvement without worsening MASH. These are assessed by liver biopsy comparison between baseline and end of treatment.
• Why it matters: MASH has very limited treatment options. Resmetirom (Rezdiffra) was the first approved drug, but retatrutide's dramatically superior liver fat reduction (up to 86% in Phase 2) could make it a transformative therapy for this condition.
• Dual indication potential: A positive TRIUMPH-4 result could lead to an FDA approval specifically for MASH, in addition to an obesity indication -- creating a dual-use drug that addresses both the cause (obesity) and one of its most dangerous consequences (liver disease).

The Regulatory Pathway to Approval

Understanding the steps between trial completion and patient access:

What Could Delay or Derail Approval

While Phase 2 data is very encouraging, several scenarios could delay FDA approval:

• Unexpected safety signals: Larger Phase 3 trials may reveal rare adverse events not seen in Phase 2. Liver enzyme elevations, cardiovascular effects from the glucagon component, or other unexpected findings could require additional study or dosing modifications.
• Efficacy attenuation: Phase 3 results sometimes show lower efficacy than Phase 2, particularly in more diverse patient populations. If 24% weight loss drops to 18%, retatrutide would still be effective but less differentiated from tirzepatide.
• Manufacturing challenges: Scaling up production of a complex triple-agonist peptide from clinical trial quantities to commercial supply is technically challenging. Manufacturing delays could push back the submission timeline.
• Regulatory requirements: The FDA may request additional studies, longer follow-up, or specific safety monitoring plans that extend the review timeline.
• Competitive landscape: The fast-moving obesity drug market means Eli Lilly may adjust their strategy based on competitor approvals and market conditions.

What Patients Should Do While Waiting

The TRIUMPH trials represent exciting science, but they should not prevent you from pursuing effective treatment available today:

• Start treatment now. Semaglutide and tirzepatide are FDA-approved and produce meaningful weight loss. Explore available options.
• Consider clinical trial enrollment. If you want access to retatrutide before FDA approval, participating in a TRIUMPH trial is the legitimate path. Search ClinicalTrials.gov for enrollment opportunities.
• Stay informed. Follow Eli Lilly's investor communications and medical conference presentations for trial updates. Results are typically first presented at medical conferences like ObesityWeek and the ADA Scientific Sessions.
• Prepare for transition. If you start semaglutide or tirzepatide now, you build valuable experience with GLP-1 therapy that will help you and your provider make informed decisions about retatrutide when it becomes available.

Learn more about how GLP-1 treatment works at Trimi and start your weight loss journey with proven medications available today.